Clustering of hepatitis C virus antibody positivity within households and communities in Punjab, India.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
07 10 2019
Historique:
entrez: 8 10 2019
pubmed: 8 10 2019
medline: 25 3 2020
Statut: epublish

Résumé

To better understand hepatitis C virus (HCV) epidemiology in Punjab state, India, we estimated the distribution of HCV antibody positivity (anti-HCV+) using a 2013-2014 HCV household seroprevalence survey. Household anti-HCV+ clustering was investigated (a) by individual-level multivariable logistic regression, and (b) comparing the observed frequency of households with multiple anti-HCV+ persons against the expected, simulated frequency assuming anti-HCV+ persons are randomly distributed. Village/ward-level clustering was investigated similarly. We estimated household-level associations between exposures and the number of anti-HCV+ members in a household (N = 1593 households) using multivariable ordered logistic regression. Anti-HCV+ prevalence was 3.6% (95% confidence interval 3.0-4.2%). Individual-level regression (N = 5543 participants) found an odds ratio of 3.19 (2.25-4.50) for someone being anti-HCV+ if another household member was anti-HCV+. Thirty households surveyed had ⩾2 anti-HCV+ members, whereas 0/1000 (P < 0.001) simulations had ⩾30 such households. Excess village-level clustering was evident: 10 villages had ⩾6 anti-HCV+ members, occurring in 31/1000 simulations (P = 0.031). The household-level model indicated the number of household members, living in southern Punjab, lower socio-economic score, and a higher proportion having ever used opium/bhuki were associated with a household's number of anti-HCV+ members. Anti-HCV+ clusters within households and villages in Punjab, India. These data should be used to inform screening efforts.

Identifiants

pubmed: 31587676
doi: 10.1017/S0950268819001705
pii: S0950268819001705
pmc: PMC6805795
doi:

Substances chimiques

Hepatitis C Antibodies 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e283

Commentaires et corrections

Type : CommentIn

Références

Hepat Med. 2017 Jun 14;9:27-33
pubmed: 28652827
J Gastroenterol Hepatol. 2019 Feb;34(2):321-329
pubmed: 30176181
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Liver Int. 2011 Jul;31 Suppl 2:61-80
pubmed: 21651703
PLoS One. 2017 May 5;12(5):e0177022
pubmed: 28475637
BMJ. 2011 Mar 22;342:d1694
pubmed: 21427048
PLoS One. 2012;7(12):e51194
pubmed: 23236452
J Clin Exp Hepatol. 2016 Sep;6(3):224-232
pubmed: 27746619
J Viral Hepat. 2000 Mar;7(2):93-103
pubmed: 10760039
Int J STD AIDS. 2014 Jul;25(8):596-606
pubmed: 24352120
J Korean Med Sci. 1994 Dec;9(6):444-9
pubmed: 7786439
Eur J Epidemiol. 1996 Feb;12(1):45-50
pubmed: 8817177
Pediatr Infect Dis J. 1994 Oct;13(10):886-9
pubmed: 7854888
J Infect Public Health. 2014 Jul-Aug;7(4):345-55
pubmed: 24861642
Epidemiol Infect. 1999 Dec;123(3):515-8
pubmed: 10694166
Crit Rev Microbiol. 2018 Mar;44(2):143-160
pubmed: 28539069
Eur J Epidemiol. 1999 Feb;15(2):125-32
pubmed: 10204641
J Urban Health. 2013 Aug;90(4):699-716
pubmed: 22733170
Am J Trop Med Hyg. 2017 Dec;97(6):1920-1928
pubmed: 29141707
J Neuroimmune Pharmacol. 2010 Dec;5(4):496-506
pubmed: 20559752
Gastroenterol Hepatol Bed Bench. 2016 Fall;9(4):250-258
pubmed: 27895850
J Med Virol. 2013 Apr;85(4):608-14
pubmed: 23417615
World J Gastroenterol. 2016 Jan 28;22(4):1684-700
pubmed: 26819533
PLoS One. 2018 Jul 26;13(7):e0200461
pubmed: 30048454
World J Hepatol. 2015 Sep 28;7(21):2323-30
pubmed: 26413221
Int J Epidemiol. 1998 Jun;27(3):525-9
pubmed: 9698147

Auteurs

A Trickey (A)

Population Health Sciences, University of Bristol, Bristol, UK.
National Institute of Health Research (NIHR) Health Protection Research Unit (HPRU) in Evaluation of Interventions at the University of Bristol, Bristol, UK.

A Sood (A)

Dayanand Medical College, Civil lines, Tagore Nagar, Ludhiana, Punjab, India.

V Midha (V)

Dayanand Medical College, Civil lines, Tagore Nagar, Ludhiana, Punjab, India.

W Thompson (W)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

C Vellozzi (C)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

S Shadaker (S)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

V Surlikar (V)

MSD India Pvt. Ltd, Mumbai, India.

S Kanchi (S)

MSD India Pvt. Ltd, Mumbai, India.

P Vickerman (P)

Population Health Sciences, University of Bristol, Bristol, UK.
National Institute of Health Research (NIHR) Health Protection Research Unit (HPRU) in Evaluation of Interventions at the University of Bristol, Bristol, UK.

M T May (MT)

Population Health Sciences, University of Bristol, Bristol, UK.
National Institute of Health Research (NIHR) Health Protection Research Unit (HPRU) in Evaluation of Interventions at the University of Bristol, Bristol, UK.

F Averhoff (F)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH